Although considerable knowledge has been gained over the last decade with respect to the clinical behaviour, prognosis, and therapeutic options for the classical oncogenic driver mutations in NSCLC, there are limited real-world data characterizing the clinical course among patients harbouring atypical EGFR and HER2 alterations in the evolving therapeutic landscape. Here, EGFR is linked to non-small cell lung carcinoma.